Biotest makes Move for US Market
Business Review Editor
Abstract
Biotest acquired the biologics strategic business unit from Nabi Biopharmaceuticals for about US$185 M in cash.
Full Text: pdf
Add comment

This work is licensed under a Creative Commons Attribution 3.0 License.